A Phase 3 interventional study of Gefurulimab in Generalized Myasthenia Gravis and gMG, sponsored by Alexion Pharmaceuticals, Inc.. Recruiting at 13 sites in 5 countries. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-04-01.
Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Myasthenia Gravis by AstraZeneca — 8 open to participants now, 11 under way, 4 of them phase 3. Myasthenia Gravis · AstraZeneca.
Among the 19 studies in Myasthenia Gravis by AstraZeneca, this one is the 10th largest by planned enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2024, is one of 9 in phase 3, reaches primary completion later than 2 of the 10 other live ones, and was the 12th registered.
331 studies on the registry are indexed under Myasthenia Gravis; 145 are open to participants now.
Browse Myasthenia Gravis studies →8 of the 19 studies in Myasthenia Gravis by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:
Alexion Pharmaceuticals, Inc. · Sites in China
Ages 18–130
Alexion Pharmaceuticals, Inc. · Sites in United States, Germany, Italy and 1 more country
Ages 18+
AstraZeneca · Sites in Russia
Ages 18+
Alexion Pharmaceuticals, Inc. · Sites in Italy
Ages 18+
AstraZeneca · Sites in Poland
Ages 18+
By country, each count listing its studies:
Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.
This study: 6 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 3 started in 2024.
This study's planned enrollment of 12 is below the median of 44 across 218 interventional studies indexed under Myasthenia Gravis.
Median enrollment 20 across the 13 interventional studies, 263 across the 6 observational. Of the 7 that completed or were terminated, 6 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Alexion Pharmaceuticals, Inc., one of the names counted as AstraZeneca. Under that name alone:
Alexion Pharmaceuticals, Inc. is the lead sponsor of 255 studies on the registry; 23 are open to participants now.
Of its 101 completed or terminated interventional studies of FDA-regulated products, 75 (74%) have results posted.
4 of the studies in Myasthenia Gravis by AstraZeneca that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06607627Phase 3Alexion Pharmaceuticals, Inc.PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis | 2026-12-15 |
| NCT07596784Phase 3Alexion Pharmaceuticals, Inc.Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG) | 2027-08-24 |
| NCT06967480Alexion Pharmaceuticals, Inc.Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis | 2027-06-30 |
| NCT07221838Alexion Pharmaceuticals, Inc.A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab | 2027-08-27 |
Add all 4 to your calendar (.ics) → With an account.
Among the 19 studies in Myasthenia Gravis by AstraZeneca, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to assess the pharmacokinetics and pharmacodynamics of gefurulimab in pediatric participants with AChR+ gMG for the duration of the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
United States of America (USA) specific inclusion criterion:
Rest of World (ROW) specific inclusion criteria:
Global inclusion criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
On Day 1, participants will receive a weight based loading dose followed by a weekly maintenance dose for up to 122 weeks.
Combination Product: Gefurulimab
Combination product consisting of syringe prefilled with gefurulimab will be administered weekly via subcutaneous (SC) injection.
Maximum Observed Serum Concentration (Cmax) of Gefurulimab
Time frame: Day 1 predose through Week 18 predose
Serum Free Complement Component 5 (C5) Concentration
Time frame: Day 1 predose through Week 18 predose
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
Time frame: Day 1 through Week 134
Change in Quantitative Myasthenia Gravis Score for Disease Severity (QMG) Total Score From Baseline Through Week 18
Time frame: Baseline through Week 18
Number of Participants With ≥ 5-point Reduction From Baseline in the QMG Total Score Through Week 18
Time frame: Baseline through Week 18
Change in Myasthenia Gravis Activities of Daily Living Profile (MG-ADL) Total Score From Baseline Through Week 18
Time frame: Baseline through Week 18
Number of Participants With ≥ 3-point Reduction From Baseline in the MG-ADL Total Score Through Week 18
Time frame: Baseline through Week 18
Number of Participants With Anti-drug Antibodies (ADAs)
Time frame: Baseline through Week 134
Number of ADA Positive Participants With Pre-existing Immunoreactivity,Treatment-emergent or Treatment-boosted ADA Responses
Time frame: Baseline through Week 134
Number of ADA Positive Participants With Neutralizing Antibody (NAb) Positive or Negative Status
Time frame: Baseline through Week 134
Not enrolling at this site.
Not enrolling at this site.
Plan to share: Yes — Alexion has a public commitment to allow requests for access to study data and will be supplying a protocol, CSR, and plain language summaries.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
No publications or documents are linked to this record.
Started Nov 2024 (actual). Primary completion is estimated for Dec 2026, 25 months after the start.
Of 43 industry-sponsored phase 3 interventional studies under Myasthenia Gravis, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 39. This study's planned 25 months is close to that.
Counting every sponsor, half of 52 studies reached it within 30 months; a quarter within 20 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Gefurulimab
Alexion Pharmaceuticals, Inc. →